Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Clonal evolution of chemotherapy-resistant urothelial carcinoma.

Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, Rosenberg J, Mosquera JM, Robinson B, Elemento O, Sboner A, Beltran H, Demichelis F, Rubin MA.

Nat Genet. 2016 Dec;48(12):1490-1499. doi: 10.1038/ng.3692. Epub 2016 Oct 17.

3.

Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma.

Thomsen MB, Nordentoft I, Lamy P, Høyer S, Vang S, Hedegaard J, Borre M, Jensen JB, Ørntoft TF, Dyrskjøt L.

Mol Oncol. 2016 Nov;10(9):1450-1460. doi: 10.1016/j.molonc.2016.08.003. Epub 2016 Aug 17.

4.

Treatment resistance in urothelial carcinoma: an evolutionary perspective.

Vlachostergios PJ, Faltas BM.

Nat Rev Clin Oncol. 2018 Aug;15(8):495-509. doi: 10.1038/s41571-018-0026-y. Review.

PMID:
29720713
5.

p53 and chemosensitivity in bladder cancer.

Nishiyama H, Watanabe J, Ogawa O.

Int J Clin Oncol. 2008 Aug;13(4):282-6. doi: 10.1007/s10147-008-0815-x. Epub 2008 Aug 15. Review.

PMID:
18704627
6.

Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma.

Lamy P, Nordentoft I, Birkenkamp-Demtröder K, Thomsen MB, Villesen P, Vang S, Hedegaard J, Borre M, Jensen JB, Høyer S, Pedersen JS, Ørntoft TF, Dyrskjøt L.

Cancer Res. 2016 Oct 1;76(19):5894-5906. Epub 2016 Aug 3.

7.

Mutational context and diverse clonal development in early and late bladder cancer.

Nordentoft I, Lamy P, Birkenkamp-Demtröder K, Shumansky K, Vang S, Hornshøj H, Juul M, Villesen P, Hedegaard J, Roth A, Thorsen K, Høyer S, Borre M, Reinert T, Fristrup N, Dyrskjøt L, Shah S, Pedersen JS, Ørntoft TF.

Cell Rep. 2014 Jun 12;7(5):1649-1663. doi: 10.1016/j.celrep.2014.04.038. Epub 2014 May 15.

8.

Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.

Scott SN, Ostrovnaya I, Lin CM, Bouvier N, Bochner BH, Iyer G, Solit D, Berger MF, Lin O.

Cancer Cytopathol. 2017 Jun;125(6):416-426. doi: 10.1002/cncy.21847. Epub 2017 Mar 24.

9.

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF.

Nature. 2012 Jan 11;481(7382):506-10. doi: 10.1038/nature10738.

10.

Clonal origin of lymph node metastases in bladder carcinoma.

Jones TD, Carr MD, Eble JN, Wang M, Lopez-Beltran A, Cheng L.

Cancer. 2005 Nov 1;104(9):1901-10.

11.

Loss of e-cadherin and retinoblastoma genes in a case of urothelial carcinoma with scrotal metastasis.

Norberg SM, Oros M, Manucha V, Eun D, Bilusic M.

Can J Urol. 2015 Apr;22(2):7755-7.

PMID:
25891343
12.

Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.

Oing C, Rink M, Oechsle K, Seidel C, von Amsberg G, Bokemeyer C.

J Urol. 2016 Feb;195(2):254-63. doi: 10.1016/j.juro.2015.06.115. Epub 2015 Sep 26. Review.

PMID:
26410730
13.

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.

Höhn A, Krüger K, Skowron MA, Bormann S, Schumacher L, Schulz WA, Hoffmann MJ, Niegisch G, Fritz G.

Oncotarget. 2016 Jul 5;7(27):41320-41335. doi: 10.18632/oncotarget.9321.

14.

Spatial intratumoral heterogeneity and temporal clonal evolution in esophageal squamous cell carcinoma.

Hao JJ, Lin DC, Dinh HQ, Mayakonda A, Jiang YY, Chang C, Jiang Y, Lu CC, Shi ZZ, Xu X, Zhang Y, Cai Y, Wang JW, Zhan QM, Wei WQ, Berman BP, Wang MR, Koeffler HP.

Nat Genet. 2016 Dec;48(12):1500-1507. doi: 10.1038/ng.3683. Epub 2016 Oct 17.

15.

Determining the origin of synchronous multifocal bladder cancer by exome sequencing.

Acar Ö, Özkurt E, Demir G, Saraç H, Alkan C, Esen T, Somel M, Lack NA.

BMC Cancer. 2015 Nov 9;15:871. doi: 10.1186/s12885-015-1859-8.

16.

MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.

Ho IL, Kuo KL, Liu SH, Chang HC, Hsieh JT, Wu JT, Chiang CK, Lin WC, Tsai YC, Chou CT, Hsu CH, Pu YS, Shi CS, Huang KH.

Sci Rep. 2015 Nov 23;5:16948. doi: 10.1038/srep16948.

17.

Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.

Kojima Y, Takahi Y, Ichimaru N, Okumi M, Takahara S, Nonomura N.

BMC Res Notes. 2015 Feb 4;8:25. doi: 10.1186/s13104-015-0982-6.

18.

Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma.

Pinciroli P, Won H, Iyer G, Canevari S, Colecchia M, Giannatempo P, Raggi D, Pierotti MA, De Braud FG, Solit DB, Rosenberg JE, Berger MF, Necchi A.

Clin Genitourin Cancer. 2016 Feb;14(1):e81-90. doi: 10.1016/j.clgc.2015.07.017. Epub 2015 Aug 7. No abstract available.

19.

Novel biomarkers in bladder cancer.

Cheng ML, Iyer G.

Urol Oncol. 2018 Mar;36(3):115-119. doi: 10.1016/j.urolonc.2018.01.009. Epub 2018 Feb 19. Review.

PMID:
29472156
20.

Genomic case report of a low grade bladder tumor metastasis to lung.

Van Every MJ, Dancik G, Paramesh V, Gurda GT, Meier DR, Cash SE, Richmond CS, Guin S.

BMC Urol. 2018 Sep 3;18(1):74. doi: 10.1186/s12894-018-0386-8.

Supplemental Content

Support Center